AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
Biomarkers, Immunotherapy, and a New Standard of Care: What's Changing in Colorectal Cancer
By Deepak Vadehra, DO
Three themes are reshaping how colorectal cancer is managed across every disease stage: a broad push to de-escalate treatment through non-operative management and radiation omission in rectal cancer
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.